Introduction
Prostate cancer is the most common solid tumor diagnosed in men in the United States. Estimates indicate 186,000 new diagnoses and 28,000 deaths from prostate cancer in 2008 [1] . Bone metastases are common in advanced prostate cancer and are associated with significant morbidity, including pain. Androgen deprivation therapy is the mainstay of treatment for advanced prostate cancer, but virtually all men with metastatic disease will eventually develop castrate-resistant prostate cancer (CRPC). Patients with CRPC have a poor prognosis with a median survival of approximately 18 months [2] . While chemotherapy with docetaxel plus prednisone has been shown to prolong median overall survival, the median improvement is only 2-2.5 months [3] [4] [5] . Clearly, new agents are needed for the treatment of CRPC to delay disease progression and improve quality of life.
Endothelins (ETs) and their receptors play an important role in cell growth and survival and have been implicated in tumor development and progression. The ETs constitute a family of three closely related 21-amino acid peptides, ET-1, -2, and -3, that are expressed by a variety of mammalian cells and exert paracrine and autocrine effects through the ET receptors, ET A and ET B , to modulate normal physiologic functions such as vasomotor tone, cell proliferation, tissue differentiation and hormone production [6] [7] [8] [9] [10] . Accumulating evidence suggests that the tumorigenic effects of ET-1 are mediated by binding to the ET A receptor. Overexpression of the ET A receptor has been reported in several human cancer cell lines and tumor types, including prostate, ovary, cervix, breast, colon, lung, kidney cancers as well as in bone metastases [6] and activation of the ET A receptor is involved in the regulation of mitogenesis, apoptosis, angiogenesis, metastasis and bone remodeling in tumors. The role of the ET A receptor in these neoplastic processes has made it an attractive therapeutic target for novel anti-cancer agents.
A growing body of evidence suggests that the ET-1/ET A receptor axis is involved in the pathophysiology of prostate cancer. ET-1 is produced by epithelial cells in the normal prostate, and seminal fluid has the highest concentrations of ET-1 in the body [11] . Elevated ET-1 concentrations [12] and increased ET A receptor expression have both been demonstrated in prostate cancer [13, 14] . In addition, an evaluation of circulating ET-1 showed that men with castrate-resistant prostate cancer (CRPC) had plasma ET-1 levels that were two times higher than those found in men with organ-confined disease or in men without prostate cancer [15] . Increases in ET-1 levels may result from decreased protease cleavage, and loss of neutral endopeptidase 24.11, a cell-surface enzyme involved in deactivation of ET-1, has been linked to the progression of prostate cancer cells to an androgen independent state [16] . In cancer cell lines, exogenous ET-1 has been shown to induce proliferation, and the mitogenic effect was enhanced by the addition of other growth factors, suggesting that ET-1 may act synergistically with other growth factors to promote the progression of prostate cancer [12] . The effects of ET-1 were inhibited by a selective ET A receptor antagonist, but not by an ET B receptor antagonist [12] .
Studies have shown that ET-1 and ETs may be involved in mediating nociceptive effects and in osteoblastic activity in prostate cancer. Studies have shown that ET-1 stimulates mitogenesis in osteoblasts [15, 17] and decreases osteoclast-mediated bone resorption and osteoclast motility [18] . ET-1 levels are elevated in men with prostate cancer who have osteoblastic metastases, and cell culture and xenograft studies have shown that ET-1 produced by prostate tumors resulted in increased osteoblastic activity and inhibited osteoclast function [17, 19, 20] . This effect was diminished by an ET A receptor-selective antagonist [17] . Clinical testing of an orally bioavailable, selective ET A receptor antagonist, atrasentan (ABT-627, Abbott Laboratories), has demonstrated benefit in prostatespecific antigen (PSA) progression, markers of bone turnover, and pain in men with prostate cancer, but has not demonstrated significant improvement in survival or time to cancer progression [19, 21] .
Zibotentan (ZD4054) is a nonpeptide, orally bioavailable, specific inhibitor of the ET A receptor [22] . In mouse erythroleukemic cells, it shows high affinity for ET A without measurable affinity for the ET B receptor [23] . In a randomized, placebo-controlled trial with healthy male volunteers, administration of a single oral dose of zibotentan resulted in reduction of the vasoconstrictive effects of ET-1 on the brachial artery [23] . This effect was mediated by the specific inhibition of the ET A receptor, and no effect was seen on ET B receptor signaling.
Based on results from the dose finding study performed in healthy volunteers and the proposed mechanism of action in prostate cancer, we conducted a multicenter, Phase I dose-escalation study of zibotentan in men with metastatic, castrate-refractory prostate cancer.
Materials and methods

Patient selection
Eligible patients had histologically-or cytologicallyconfirmed metastatic adenocarcinoma of the prostate and evidence of disease progression (defined radiographical progression on bone or computed tomography scan or increasing PSA confirmed on two consecutive measurements, with a minimum PSA value ≥5 ng/ml). All patients had to have evidence of castrate-resistant disease as evident by a serum testosterone level of ≤50 ng/dl. Patients who were on an LHRH agonist or an anti-androgen were required to continue them for the duration of the study. Patients who discontinued anti-androgen therapy were required to wait at least 6 weeks prior to enrollment to exclude an anti-androgen withdrawal response. Other entry criteria included: age ≥18; World Health Organization performance status of 0-1; adequate hepatic function (total bilirubin ≤1.5 x the institutional upper limit of normal (ULN) and alanine aminotransferase and aspartate aminotransferase ≤3 x the institutional ULN); adequate renal function as defined by a calculated (Cockcroft-Gault formula) creatinine clearance ≥60 ml/min; and a life expectancy of at least 3 months. Exclusion criteria included the following: >2 prior systemic therapies ; ≤4 weeks since prior chemotherapy or radiation therapy; initiation of a bisphosphonate within 4 weeks; epilepsy or other seizure disorder; concurrent therapy with a significant CYP3A4 inhibitor; evidence of prolonged QTc interval; and any serious concomitant medical conditions that would place the patient at excessive or unacceptable risk of toxicity. Written informed consent was obtained from all patients, and the study protocol was approved by the Institutional Review Boards of the participating institutions.
Study design
This was a multi-center, open-label, non-randomized, Phase I dose-escalation study to determine the safety and tolerability of zibotentan given orally in men with metastatic CRPC to determine the MWTD. Secondary endpoints were effects on PSA levels, effect on biomarkers of bone turnover and analysis of pharmacokinetics (PK). The initial cohort received 28 daily doses (Period 1). Patients who had evidence of clinical benefit during the first 28 days were continued until there was a dose-limiting toxicity (DLT) or evidence of disease progression (Period 2).
Treatment plan
Zibotentan tablets were supplied by AstraZeneca (Macclesfield, UK) and were administered orally once daily. The starting dose of zibotentan in the first cohort (Period 1) was 10 mg daily, and dose escalation proceeded in a stepwise fashion (15 mg, 22.5 mg, 32.5 mg and 50 mg) in cohorts of three patients, with an initial planned maximum of 200 mg daily. The initial cohort received 28 doses over 29 days (no dose was given on day 2 to allow PK determination). For dose escalation to occur, three assessable patients had to complete at least seven doses of zibotentan at the 10 mg or 15 mg dose levels during days 1 through 8 without a DLT or 14 doses of zibotentan >15 mg during days 1 through 15 without a DLT. However, determination of MWTD was based on safety analysis through the entire 29-day period for all patients. Dose escalation occurred in the standard 3-by-3 fashion. The MWTD was defined as the dose level below that at which >1 out of 3 or ≥2 out of 6 evaluable patients experienced DLTs. No intra-patient dose escalation was permitted, and dose reduction for patients who experienced a DLT was not allowed for the determination of the MWTD.
DLT was evaluated by National Cancer Institute Common Toxicity Criteria 2.0 and defined as a toxicity that was at least possibly related to zibotentan including: grade ≥3 headache with onset within 24 h of receiving zibotentan despite maximum supportive care; grade ≥2 rhinitis leading to withdrawal from protocol; and any other grade ≥3 toxicity deemed related to treatment.
Since headache and rhinitis have been observed with other ET A -receptor antagonists, patients were proactively monitored for these symptoms. Any patient reporting a headache was instructed to take acetaminophen 1 g immediately at onset, to be repeated every 4 h (maximum 4 g per 24-hour period) until resolution of the headache. If the headache persisted or worsened despite the administration of full-dose acetaminophen, treatment was left to the discretion of the treating physician. Patients with ongoing headaches were given an ongoing supply of analgesics and instructed to document any doses taken and the time of resolution of the headache. Patients experiencing rhinitis were treated with over-the-counter decongestants or antihistamines as needed.
All patients were scheduled to receive at least the initial course of 28 oral doses over 29 days (Period 1). Patients who had evidence of clinical benefit and who had not met any of the criteria for withdrawal were allowed to receive zibotentan at their current dose level until they no longer derived clinical benefit, experienced a DLT that did not resolve to CTC grade ≤1 or met other withdrawal criterion. Dose reduction was only permitted for patients who experienced a DLT after consultation with AstraZeneca and the principal investigators. Each additional cycle was considered to be 28 days in length. All study-related procedures were performed during the extension period at the specific times outlined below.
Pretreatment and follow-up studies
After baseline assessments including a complete medical history, physical examination, laboratory studies (CBC, PTT, INR, chem7, PSA and urinalysis) and a 12-lead electrocardiogram (EKG) were performed, the complete blood counts and serum chemistries were repeated weekly for the first month, and then at the beginning of each new course (every 4 weeks) of therapy. Vital signs, performance status, PSA, bone markers, urinalysis, 12-lead EKG and toxicity were also assessed weekly for the first month, and then at the beginning of each additional course of therapy thereafter. Routine laboratory assessments included: complete blood count, electrolytes, BUN and creatinine. Bone markers included: bone alkaline phosphatase (ALP), procollagen type I N propeptide (PINP), C-terminal telopeptide of type I collagen (CTx) and type I collagen-cross-linked N telopeptide (NTx). A baseline bone scan was also performed within 12 weeks prior to enrollment if applicable. 
Zibotentan plasma concentrations were determined for all patients using high-performance liquid chromatography with tandem mass-spectrometric detection by York Bioanalytical Solutions Ltd, Upper Poppleton, York, UK. Non-compartmental methods were used by AstraZeneca for the evaluation of plasma concentration-time data following the single-dose administration of zibotentan and on day 29 of the multiple-dose phase. The maximum observed plasma concentration (C max ) and the time of C max (t max ) were determined by inspection of the plasma concentration-time curve. The terminal rate constant (λz) was estimated by linear regression of the terminal portion of the logtransformed concentration-time data where there were sufficient data to determine the terminal phase (i.e., when the terminal phase could be followed for at least three halflives). The terminal half-life was calculated as 0.693/λz. The area under the plasma concentration-time curve from zero to the last measurable time-point, AUC (0-t) was calculated using the linear up-log down trapezoidal rule, and was extrapolated to infinity using λz to obtain AUC. The area under the plasma concentration-time curve from 0 to 24 h post-dose, AUC (0-24) , was calculated using the linear up-log down trapezoidal rule. The apparent clearance (CL/F) was determined from the ratio of dose/AUC and the apparent volume of distribution at steady state (Vss/F) was calculated as mean residence (MRT) x CL/F. Accumulation ratio (R ac ) was calculated as the ratio of the AUC (0-24) on day 29 and AUC (0-24) at single dose. The ratio of day 29 AUC (0-24) and the single-dose AUC was used for the evaluation of any temporal change (Tc) in the pharmacokinetics of zibotentan.
Results
Patient characteristics
Between June 2003 and October 2005, 16 patients were enrolled in this study at two participating sites. Median age was 65 years (range 49-81), 15 patients were Caucasian and 1 Black, and all had a performance status of 0-1. Eleven patients completed Period 1, and nine patients completed Period 2. Of the five patients who discontinued therapy during Period 1, two stopped at the 15 mg dose level (one due to progressive disease and one due to toxicity) and three stopped at the 22.5 mg dose level (one for an erroneously reported QTc prolongation and two due to toxicity). All 16 patients were included in the safety analysis and the single-dose PK analysis. Eleven patients were included in the multiple-dose PK analysis.
Dose escalation and toxicity
No DLTs were observed in the patients who received the starting dose of 10 mg, or in those who received 15 mg. Four patients were enrolled at the dose level 22.5 mg, two of whom experienced DLTs (grade 3 peripheral edema and grade 3 intraventricular hemorrhage). One patient received one dose of 22.5 mg and was later dose reduced to 15 mg. This subject has been classified into the 15 mg group for safety and multiple-dose PK, and into the 22.5 mg group for single-dose PK. Adverse events are summarized in Table 1 . The main toxicity associated with zibotentan in this study was headache, and other common toxicities included peripheral edema, fatigue, arthralgia, rhinitis, nausea and sinus congestion. Most patients did not experience any AEs of grade ≥3, with the exception of the two patients who experienced DLTs in the 22.5 mg cohort, one patient in the 15 mg cohort, and two patients in the 10 mg cohort (Table 2 ). There were no deaths on study, but one patient died due to progressive disease after withdrawal from the study.
Efficacy
Although not a primary endpoint of this trial, patients underwent disease assessment following every cycle of therapy. While no objective antitumor responses were seen, nine patients (three receiving 10 mg and 6 receiving 15 mg) tolerated therapy and had evidence of clinical benefit with stable PSA levels or imaging during Period 1. Of the six patients treated during Period 2, there was no evidence of PSA response; however, a transient decrease in the rise in PSA levels was observed in patients who continued on treatment (data not shown).
Zibotentan pharmacokinetics
Single-dose PK studies of zibotentan were conducted in all 16 patients ( Fig. 1; Table 3 ), and multiple-dose PK analysis was performed in 11 patients (Table 4) . Absorption was rapid, with t max generally being achieved between 1 and 4 h post dose. Assessment of C max , AUC and AUC (0−t) values following single-and multiple-dose administration of zibotentan revealed that exposure increased proportionately with dose. The single-dose PK data showed that the apparent clearance and volume of distribution were low, and the mean terminal half-life was between 7.0 and 9.2 h at all three dose levels. Minimal accumulation of zibotentan was observed with repeat dosing, steady-state concentrations were achieved by at least day 8 of treatment (5 days of daily administration), and no temporal change in the PK of zibotentan was seen after repeated dosing.
Pharmacodynamic analysis
Assessment of bone markers (bone ALP, PINP, CTx and NTx) showed considerable intra-and inter-patient variability (data not shown). Because of the small number of patients in relation to the large variability, it was not possible to make any definitive conclusions or draw any general trends from these pharmacodynamic endpoints.
Discussion
The rationale for ET receptor antagonism as a treatment modality in prostate cancer is scientifically compelling as ET receptor antagonists can provide direct antitumor effects, and also impact the tumor environment, by inhibiting osteoblast proliferation, bone remodeling, and the release of growth factors that may aid the spread of tumor within osseous metastases. Prior studies with atrasentan (ABT-627, Abbott Laboratories), a selective ET receptor antagonist, also currently in clinical development, showed an improvement in pain and a trend towards improvement in time to progression (vs. placebo) [19, 21] , and ongoing trials with this agent are being conducted.
Zibotentan is a specific ET A receptor antagonist (unlike atrasentan which has some ET B receptor affinity). By inhibiting only the ET A receptor, the beneficial effects of ET B activation on apoptosis and antinociceptive effects should be preserved. This Phase I dose-escalation study of the specific ET A -receptor antagonist, zibotentan, in men with metastatic CRPC, showed that continuous oral A multi-center, Phase II, randomized, double blind, placebo-controlled trial with zibotentan has since been performed [24, 25] . A total of 312 asymptomatic or mildly symptomatic patients with CRPC and bone metastasis were randomized into one of three treatment arms: 15 mg zibotentan once daily; 10 mg zibotentan once daily or placebo. The primary end point was progression free survival (PFS) using a composite end point, with the secondary end point being overall survival (OS). While there was not a statistically significant difference in PFS between the zibotentan and placebo arms, preliminary survival data suggested an improvement in OS. These results suggest that zibotentan may be providing clinical efficacy in prostate cancer. Phase III studies are currently being performed to further evaluate the efficacy of zibotentan. Given the relatively benign side effect profile of zibotentan, it can be envisaged that this agent may also be co-administered with other anticancer agents to provide additional efficacy. A combination study with docetaxel forms part of the Phase III program, and it will be of interest to learn if there are additive or synergistic effects of zibotentan in terms of improved efficacy or symptom management when administered with chemotherapy.
In addition to prostate cancer, early studies showed that ETs and their receptors are expressed in several other cell lines and tumor types [9] , and may play a role in several other cancers, including ovary [26] , cervix [27, 28] , breast [29] , melanocytes [30] , kidney [31] , lung, colon, central nervous system, and in Kaposi's sarcoma [6] . While the clinical activity of the ET-1/ET receptor axis has been studied primarily in prostate cancer, preclinical work is ongoing to determine whether ET A receptor antagonists may be effective in the treatment of other tumour types. Future clinical studies will also evaluate zibotentan in responsive tumors.
In summary, this study was designed to determine the MWTD of oral zibotentan in patients with CRPC. Oral administration of zibotentan given continuously daily was well tolerated, with the MWTD determined to be 15 mg daily. Zibotentan has a favorable PK profile for continuous daily dosing. Phase III trials evaluating zibotentan in patients with CRPC, with rising PSA and no evidence of radiographical metastasis, as well as those with asymptomatic metastatic CRPC are currently underway to assess whether zibotentan can improve overall survival. Likewise, a Phase III trial assessing docetaxel with or without zibotentan is being undertaken in chemotherapy-naïve patients.
